Morphological Changes in Bone Marrow Post Imatinib Therapy in Chronic Phase CML: A Follow up Study on Sequential Bone Marrow Aspirates and Biopsies
Journal Title: Journal of Clinical and Diagnostic Research - Year 2017, Vol 11, Issue 4
Abstract
Introduction: Imatinib mesylate is used extensively for first line treatment of Chronic Myeloid Leukemia (CML). However, not many studies have documented morphological changes in bone marrow biopsies produced during Imatinib therapy with reference to myelofibrosis. Aim: To document the morphological changes produced in the bone marrow during Imatinib therapy. Materials and Methods: This longitudinal study followed up 75 Philadelphia Chromosome Positive Chronic Myeloid Leukemia with chronic phase(Ph+ CML- CP) patients sequentially, receiving 400-600mg Imatinib over a period of 12 or more months. Haematologic parameters were measured at admission, 2 weeks, 1 month, 3 months, 6 months and 12 or more months. Morphologic changes in bone marrow aspirate and biopsy were evaluated at admission, 6 months and ≥12 months of treatment in accordance with National Comprehensive Cancer Network(NCCN) guidelines. Results: Complete Haematologic Response (CHR) was seen in 47.1%, 80%, 85.4%, 90.4% at ≥1 month, 3 months, 6 months and 12 months respectively after therapy. It was noted that patients not showing CHR by 3 months were less likely to show CHR at 6 months and beyond. Bone marrow aspirates and biopsies showed reduction in cellularity and myeloid precursors with regeneration of erythroid precursors in 70-83% at ≥12 months. A significant decrease in myelofibrosis (p-value< 0.04) was noted as early as 6 months. Mild to moderate hypoplasia was noted in 31.8% of biopsies within 6 months. Pseudo gaucher cells and benign lymphoid nodules were also seen. Conclusion: Sequential analysis showed that Imatinib reduced the grade of myelofibrosis significantly (p-value< 0.04). It also prevented development of myelofibrosis in patients who did not have it at presentation. Hence Imatinib is effective when used early in the course of CML-CP.
Authors and Affiliations
Neha Chopra Narang
Keywords
Related Articles
- EP ID EP337163
- DOI 10.7860/JCDR/2017/25173.9650
- Views 110
- Downloads 0
Effect of Dexmedetomidine Versus Fentanyl on Haemodynamic Response to Patients Undergoing Elective Laparoscopic Surgery: A Double Blinded Randomized Controlled Study
Introduction: Dexmedetomidine, an a2 agonist, can be used as an adjuvant in general anaesthesia as it attenuates the stress response to various noxious stimuli and helps in maintaining the perioperative haemodynamic stab...
Congenital Midline Cervical Cleft –Clinical and Pathological Review of Three Cases
ABSTRACT We are presenting three rare cases of Congenital Midline Cervical Cleft (CMCC). All are treated by excision and Z-plasty. Embryology, clinical appearance, histopathology and treatment have been discussed with re...
Prevalence of Acanthosis nigricans and Related Factors in Iranian Obese Children
Introduction: Recognition of Acanthosis nigricans (AN) provides important opportunities for screening of obesity syndrome, dyslipidemia, hypertension and insulin resistance with diabetes mellitus 2. Considering the high...
Ebola Vaccine: How Far are we?
Ebola viruses have been identified as an emerging threat as it causes severe haemorrhagic fever in human with mortality rates ranging from 50 to 90%. In addition to being a global health concern, the virus also is consid...
Dental Anxiety in Children: A Review of the Contributing Factors
ABSTRACT Dental anxiety is a challenge faced by the dental professionals while treating young children. Many factors have been reported as contributing factors that influence and affect the level of dental anxiety in chi...